Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
Zhao Y, Li H, Bai W, Liu J, Lv W, Sahu S, Guan S, Qin X, Wang W, Ren W, Mu W, Guo W, Gu S, Ma Y, Yin Z, Guo W, Wang W, Wang Y, Duran R, Fan D, Zhang Z, Han G.
Zhao Y, et al. Among authors: bai w.
Int J Cancer. 2016 Aug 15;139(4):928-37. doi: 10.1002/ijc.30124.
Int J Cancer. 2016.
PMID: 27038145